DrugPatentWatch Database Preview
ERIVEDGE Drug Profile
When do Erivedge patents expire, and what generic alternatives are available?
Erivedge is a drug marketed by Genentech and is included in one NDA. There are two patents protecting this drug.
This drug has forty-six patent family members in twenty-three countries.
The generic ingredient in ERIVEDGE is vismodegib. One supplier is listed for this compound. Additional details are available on the vismodegib profile page.
Summary for ERIVEDGE
| International Patents: | 46 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 95 |
| Clinical Trials: | 40 |
| Patent Applications: | 61 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for ERIVEDGE |
| Prior Art and Litigation Support | Order Prior Art and Litigation support for ERIVEDGE |
| DailyMed Link: | ERIVEDGE at DailyMed |
Generic Entry Opportunity Date for ERIVEDGE
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for ERIVEDGE
| Drug Class | Hedgehog Pathway Inhibitor |
| Mechanism of Action | Smoothened Receptor Antagonists |
Synonyms for ERIVEDGE
| 085G559 |
| 2-Chloranyl-~{n}-(4-Chloranyl-3-Pyridin-2-Yl-Phenyl)-4-Methylsulfonyl-Benzamide |
| 2-chloro-n-(4-chloro-3-(2-pyridinyl)phenyl)-4-(methylsulfonyl)benzamide |
| 2-Chloro-N-(4-chloro-3-(2-pyridl)phenyl)-4-(methylsulfonyl)benzamide |
| 2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methyl sulfonyl)benzamide |
| 2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide |
| 2-chloro-N-(4-chloro-3-pyridin-2-yl-phenyl)-4-methanesulfonyl-benzamide |
| 2-chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide |
| 2-CHLORO-N-[4-CHLORO-3-(2-PYRIDINYL)PHENYL]-4-(METHYLSULFONYL)-BENZAMIDE |
| 2-Chloro-N-[4-chloro-3-(2-pyridinyl)phenyl]-4-(methylsulfonyl)benzamide |
| 2-chloro-N-[4-chloro-3-(2-pyridyl)phenyl]-4-methylsulfonyl-benzamide |
| 2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4- |
| 2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide |
| 2-chloro-N~1~-[4-chloro-3-(2-pyridyl)phenyl]-4-(methylsulfonyl)benzamide |
| 25X868M3DS |
| 4CA-1325 |
| 879085-55-9 |
| A10467 |
| AB0008125 |
| AB01565813_02 |
| ABP000894 |
| AC-26969 |
| AJ-103831 |
| AK-77261 |
| AKOS015966534 |
| AN-471 |
| ANW-60962 |
| AOB1040 |
| AS-14066 |
| AX8167197 |
| BC660083 |
| BCP01715 |
| BCP9000713 |
| BCPP000223 |
| BDBM50249522 |
| Benzamide, 2-chloro-N-(4-chloro-3-(2-pyridinyl)phenyl)-4-(methylsulfonyl)- |
| BG0661 |
| BPQMGSKTAYIVFO-UHFFFAOYSA-N |
| C19H14Cl2N2O3S |
| C538724000 |
| CHEBI:66903 |
| CHEMBL473417 |
| CS-0255 |
| CTK8B8648 |
| CUR-691 |
| D09992 |
| DB08828 |
| DTXSID40236689 |
| Erivedge (TN) |
| EX-A2178 |
| FT-0675833 |
| GD 0449|||2-Chloro-N-[4-chloro-3-(2-pyridinyl)phenyl]-4-(methylsulfonyl)benzamide |
| GDC 0449 |
| GDC-0449 |
| GDC-0449 - Selumetinib |
| GDC-0449 (Vismodegib) |
| GDC-0449, GDC0449, GDC 0449, 879085-55-9 |
| GDC-0449,Vismodegib |
| GDC-0449,Vismodegib, HhAntag691 |
| GDC-0449(Vismodegib) |
| GDC-0449(Vismodegib)/GDC0449 |
| GDC-449 |
| GDC0449 |
| GTPL6975 |
| Hh-Antag691 |
| HhAntag691 |
| HMS3604K16 |
| HMS3654E17 |
| HSDB 8130 |
| HY-10440 |
| J-509076 |
| J90022 |
| KB-308771 |
| KB-81450 |
| KS-000000BH |
| MCULE-6680076172 |
| methanesulfonylbenzamide |
| MLS006012035 |
| MolPort-009-679-417 |
| NCGC00242497-01 |
| NCGC00242497-02 |
| NCGC00242497-06 |
| NSC 747691 |
| NSC-747691 |
| NSC-755986 |
| NSC747691 |
| NSC755986 |
| PB15086 |
| PubChem19137 |
| Q-2305 |
| QCR-40 |
| R 3616 |
| R-3616 |
| RG-3616 |
| RL05479 |
| s1082 |
| SC-87729 |
| SCHEMBL302587 |
| SMR004703564 |
| SR-01000941574 |
| SR-01000941574-1 |
| ST24040458 |
| SW218087-2 |
| TC-149707 |
| UNII-25X868M3DS |
| V-4050 |
| VIS |
| Vismodegib |
| Vismodegib (GDC-0449) |
| Vismodegib (USAN/INN) |
| Vismodegib [USAN:INN] |
| Vismodegib, free base |
| Vismodegib; GDC-0449 |
| Vismodegib; HhAntag 691 |
| vismodegibum |
| X4669 |
| ZINC40899447 |
US Patents and Regulatory Information for ERIVEDGE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech | ERIVEDGE | vismodegib | CAPSULE;ORAL | 203388-001 | Jan 30, 2012 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Genentech | ERIVEDGE | vismodegib | CAPSULE;ORAL | 203388-001 | Jan 30, 2012 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for ERIVEDGE
Supplementary Protection Certificates for ERIVEDGE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1789390 | 2014/002 | Ireland | ➤ Sign Up | PRODUCT NAME: ERIVEDGE-VISMODEGIB OR A SALT OR SOLVATE THEREOF; NAT REGISTRATION NO/DATE: EU/1/13/848 20130712; FIRST REGISTRATION NO/DATE: 62497 01 20130530 |
| 1789390 | PA2013024,C1789390 | Lithuania | ➤ Sign Up | PRODUCT NAME: VISMODEGIBUM; NAT. REGISTRATION NO/DATE: SWISS 62497 01 20130530; FIRST REGISTRATION: EU/1/13/848 20130712 |
| 1789390 | CA 2013 00050 | Denmark | ➤ Sign Up | PRODUCT NAME: VISMODEGIB; NAT. REG. NO/DATE: EU71/13/848 20130712; FIRST REG. NO/DATE: CH 62497 20130530 |
| 1789390 | 514 | Finland | ➤ Sign Up | |
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
